[{"data":1,"prerenderedAt":332},["ShallowReactive",2],{"content-route-/en/treatments-evidence/candida-overgrowth-claim":3},{"state":4,"owner":4,"route":5,"locale":6,"template":7,"content":18,"projection":155,"alternates":323},"target","/en/treatments-evidence/candida-overgrowth-claim","en-US",{"kind":8,"family":9,"sectionKeys":10},"claim","guidance",[11,12,13,14,15,16,17],"established","not-shown","does-not-imply","safety-cost","alternatives","stop-pivot","evidence",{"kind":8,"title":19,"description":20,"firstPublished":21,"evidenceAsOf":21,"lastUpdated":21,"changeNote":22,"firstLayer":23,"claim":53,"relations":80,"body":104},"The \"candida overgrowth\" claim: does a broad symptom cluster prove it?","See the exact \"candida overgrowth\" claim, why current evidence does not support it at a broad, whole-body level, what is actually established, and what to do instead.","2026-07-15","Complete initial draft from the Pathway B terminology, US authority, and Polish authority packs.",{"question":24,"answer":25,"keyPoints":26,"confidence":30,"applicability":33,"nextSteps":40},"Does a broad cluster of symptoms mean I have candida overgrowth?","This broad \"candida overgrowth\" claim is not supported by current evidence, at a moderate evidence level. It is understandable to look for one explanation that ties together fatigue, bloating, brain fog, mood changes, cravings, and skin complaints, but no recognized disease definition or controlled trial currently backs whole-body Candida overgrowth as their shared cause.",[27,28,29],"A systematic review of intestinal Candida found it common in healthy adults and found no epidemiologic or therapeutic evidence for a Candida-hypersensitivity syndrome.","A controlled trial of oral nystatin in women meeting proposed candidiasis-hypersensitivity criteria found no meaningful advantage over placebo for systemic or psychological symptoms.","Recognized Candida conditions are site-specific (such as vaginal or oral candidiasis) or the distinct, high-risk entity invasive candidiasis; a positive finding or a broad symptom list alone does not establish either one.",{"summary":31,"rationale":32},"Moderate-evidence not-supported verdict for the broad \"candida overgrowth\" claim.","A systematic review of 96 eligible citations found no epidemiologic or therapeutic evidence for a Candida or Candida-hypersensitivity syndrome, current CDC and IDSA disease definitions do not recognize a symptom-list diagnosis of systemic or intestinal candidiasis, and a controlled nystatin trial found no meaningful benefit over placebo for systemic or psychological symptoms.",{"appliesTo":34,"excludes":37},[35,36],"Adolescents and adults with chronic gastrointestinal or other nonspecific symptoms who are considering, or have been told, that \"candida overgrowth\" explains them, without an established site-specific or invasive Candida diagnosis.","People deciding whether to start a supplement or diet marketed for candida overgrowth and wanting to see the evidence first.",[38,39],"People with an immediate medical emergency or acute crisis, who should use the urgent-help route now.","People with an already-diagnosed, recognized Candida condition (such as vaginal candidiasis, oral thrush, invasive candidiasis, or SIFO), whose care follows that diagnosis rather than this claim.",[41,45,49],{"label":42,"action":43,"route":44},"Prepare questions for a clinician","Use a structured worksheet to bring your exact symptoms and any candida-related claim to a clinician for evaluation.","/en/tools/candida-claim-clinician-questions",{"label":46,"action":47,"route":48},"Check the terms in play","See how candidiasis, invasive candidiasis, SIFO, and \"candida overgrowth\" differ before applying any of them to your symptoms.","/en/symptoms-conditions/candida-terms",{"label":50,"action":51,"route":52},"Review urgent routes","Confirm whether any symptom needs urgent rather than routine care.","/en/urgent-help",{"exactClaim":54,"verdictClaimId":55,"established":56,"notShown":61,"doesNotImply":64,"safetyAndCost":67,"alternatives":70,"stopPivot":78,"evidenceMapRoute":79},"A broad cluster of nonspecific symptoms such as fatigue, bloating, altered bowel habits, concentration difficulty, mood symptoms, cravings, or skin complaints establishes intestinal Candida overgrowth as their shared cause. This claim is not supported by current evidence, at a moderate evidence level.","broad-candida-symptom-cluster-establishes-cause",[57,58,59,60],"Candidiasis is a recognized disease when Candida causes site-specific disease, such as vaginal, oral, skin, or gastrointestinal candidiasis; Candida is normally present at several of these sites, so its presence alone is not disease.","Candida colonization of nonsterile sites, including the gut, mouth, skin, and respiratory tract, is common in healthy immunocompetent adults.","Invasive candidiasis, infection of the bloodstream or normally sterile internal sites, is a distinct, recognized disease entity defined by clinical risk factors and cultures; it is not another name for a self-attributed whole-body symptom pattern.","Small intestinal fungal overgrowth (SIFO) is a narrow, aspirate-culture-defined clinical-research entity studied in a selected group of people with gastrointestinal symptoms considered for specialist evaluation; it is a real but limited research finding, not a broad multisystem syndrome.",[62,63],"A systematic review of 96 eligible citations on intestinal Candida found neither epidemiologic nor therapeutic evidence for a Candida or Candida-hypersensitivity syndrome.","In a randomized, double-blind, placebo-controlled crossover trial in women meeting proposed candidiasis-hypersensitivity criteria, oral nystatin showed no meaningful advantage over placebo for systemic or psychological symptoms.",[65,66],"A broad, nonspecific symptom cluster does not by itself establish intestinal or whole-body Candida overgrowth as its cause.","Detecting Candida, or a positive Candida finding, without compatible symptoms and signs of a recognized site-specific or invasive condition does not by itself establish Candida overgrowth as the explanation for those symptoms.",[68,69],"Supplements and diets marketed for \"candida overgrowth,\" die-off, or biofilms are not verified treatments for this claim; current evidence does not establish that they treat, cure, or remove a whole-body Candida overgrowth.","Before starting a supplement marketed for candida overgrowth, have the exact product label reviewed against your medicines, other supplements, health conditions, and pregnancy status by a physician, pharmacist, or registered dietitian.",[71,75],{"label":72,"discriminator":73,"route":74},"SIFO (small intestinal fungal overgrowth)","SIFO is an aspirate-culture-defined finding in a selected group of people with gastrointestinal symptoms assessed by specialists; it is not a whole-body or self-diagnosed syndrome.","/en/symptoms-conditions/sifo",{"label":76,"discriminator":77,"route":48},"Candida and \"candida overgrowth\" terms","Distinguishes candidiasis, invasive candidiasis, colonization, and SIFO from the vernacular \"candida overgrowth\" claim before applying any of them to a symptom pattern.","When no recognized Candida condition (site-specific candidiasis, invasive candidiasis, or SIFO) has been established, stop attributing a broad symptom cluster to candida overgrowth and pivot to having the actual symptoms evaluated. Plausible alternatives to raise with a clinician include functional gastrointestinal disorders, medication effects, dietary intolerance, endocrine or hematologic disease, dermatologic conditions, sleep or mood disorders, and other infections. If considering a supplement or diet marketed for candida overgrowth, get the exact product reviewed against your medicines, conditions, and pregnancy status before starting it.","/en/research/evidence/broad-candida-claims",[81,85,88,89,91,95,98,101],{"group":82,"route":83,"label":84},"parent","/en/treatments-evidence","Treatments & evidence",{"group":86,"route":74,"label":87},"differential","SIFO",{"group":86,"route":48,"label":76},{"group":17,"route":79,"label":90},"Broad candida claims: evidence map",{"group":92,"route":93,"label":94},"research","/en/research/nystatin-candida-systemic-symptoms-1990","Nystatin for systemic candida symptoms (1990)",{"group":92,"route":96,"label":97},"/en/research/sifo-aspirate-symptoms-2013","SIFO aspirate and symptoms (2013)",{"group":99,"route":52,"label":100},"safety","Urgent help",{"group":102,"route":44,"label":103},"tool","Candida claim clinician questions",{"type":105,"value":106,"toc":151},"minimark",[107,115,121,127,133,139,145],[108,109,111],"content-section",{"section-key":11,"title":110},"What is actually established",[112,113,114],"p",{},"Candidiasis is a recognized disease when Candida causes site-specific disease, such as vaginal, oral, skin, or gastrointestinal candidiasis. Candida is normally present at several of these sites, including the gut, mouth, skin, and respiratory tract, and colonization there is common in healthy immunocompetent adults, so its presence alone is not disease. Invasive candidiasis, infection of the bloodstream or normally sterile internal sites, is a separate, recognized disease entity defined by clinical risk factors and cultures; it is not another name for a self-attributed whole-body symptom pattern. Small intestinal fungal overgrowth (SIFO) is a narrow, aspirate-culture-defined clinical-research entity studied in a selected group of people with gastrointestinal symptoms considered for specialist evaluation. It is a real but limited research finding, not a broad multisystem syndrome.",[108,116,118],{"section-key":12,"title":117},"What has not been shown",[112,119,120],{},"A systematic review of 96 eligible citations on intestinal Candida found it common in healthy adults and found neither epidemiologic nor therapeutic evidence for a Candida or Candida-hypersensitivity syndrome. In a randomized, double-blind, placebo-controlled crossover trial, women who met proposed candidiasis-hypersensitivity criteria and received oral nystatin showed no meaningful advantage over placebo for systemic or psychological symptoms. Taken together, the available research does not show that a Candida or Candida-hypersensitivity syndrome exists as a defined condition, or that treating for it changes systemic or psychological symptoms beyond placebo.",[108,122,124],{"section-key":13,"title":123},"What this does not imply",[112,125,126],{},"A broad, nonspecific symptom cluster, such as fatigue, bloating, altered bowel habits, concentration difficulty, mood symptoms, cravings, or skin complaints, does not by itself establish intestinal or whole-body Candida overgrowth as its cause. Detecting Candida, or a positive Candida finding, without compatible symptoms and signs of a recognized site-specific or invasive condition does not by itself establish Candida overgrowth as the explanation for those symptoms; colonization of nonsterile sites is common and expected in healthy people.",[108,128,130],{"section-key":14,"title":129},"Safety and cost before trying a supplement",[112,131,132],{},"Supplements and diets marketed for \"candida overgrowth,\" die-off, or biofilms are not verified treatments for this claim, and current evidence does not establish that they treat, cure, or remove a whole-body Candida overgrowth. This page does not promise or deny that any product works. Before starting a supplement marketed for candida overgrowth, have the exact product label reviewed against your medicines, other supplements, health conditions, and pregnancy status by a physician, pharmacist, or registered dietitian.",[108,134,136],{"section-key":15,"title":135},"Plausible alternatives to consider",[112,137,138],{},"When symptoms are real but a recognized Candida condition has not been established, other explanations are often more likely and worth raising with a clinician. Depending on the symptom pattern, plausible alternatives include functional gastrointestinal disorders, medication effects, dietary intolerance, endocrine or hematologic disease, dermatologic conditions, sleep or mood disorders, and other infections. The one recognized narrower entity that can resemble part of this picture is SIFO, an aspirate-culture-defined finding in a selected gastrointestinal population, not a whole-body syndrome; see the SIFO page for how it differs. See also how candidiasis, invasive candidiasis, colonization, and SIFO differ from the vernacular \"candida overgrowth\" claim on the candida terms page.",[108,140,142],{"section-key":16,"title":141},"Stop and pivot",[112,143,144],{},"When no recognized Candida condition, meaning site-specific candidiasis, invasive candidiasis, or SIFO, has been established, stop attributing a broad symptom cluster to candida overgrowth and pivot to having the actual symptoms evaluated. Bring the plausible alternatives above to a clinician rather than assuming candida overgrowth by default. If considering a supplement or diet marketed for candida overgrowth, get the exact product reviewed against your medicines, conditions, and pregnancy status before starting it.",[108,146,148],{"section-key":17,"title":147},"Evidence map and sources",[112,149,150],{},"The full trace of agreements, disagreements, and gaps behind broad candida claims, including this one, is on the broad candida claims evidence map. This page draws on CDC and IDSA disease-definition guidance, a systematic review of intestinal Candida, a controlled nystatin trial, and SIFO research; see the evidence map for how these sources relate to each other and to related claims.",{"title":152,"searchDepth":153,"depth":153,"links":154},"",2,[],{"sources":156,"claims":221,"safety":308},[157,165,169,177,185,193,201,209,216],{"sourceId":158,"title":159,"canonicalId":160,"canonicalUrl":161,"publisher":162,"sourceType":163,"publicationDate":164,"lastChecked":21},"cdc-candidiasis-basics-2024","Candidiasis Basics",null,"https://www.cdc.gov/candidiasis/about/index.html","US Centers for Disease Control and Prevention","regulator","2024-04-24",{"sourceId":166,"title":167,"canonicalId":160,"canonicalUrl":168,"publisher":162,"sourceType":163,"publicationDate":164,"lastChecked":21},"cdc-invasive-candidiasis-overview-2024","Clinical Overview of Invasive Candidiasis","https://www.cdc.gov/candidiasis/hcp/clinical-overview/",{"sourceId":170,"title":171,"canonicalId":172,"canonicalUrl":173,"publisher":174,"sourceType":175,"publicationDate":176,"lastChecked":21},"idsa-candidiasis-guideline-2016","Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","DOI:10.1093/cid/civ933","https://www.idsociety.org/practice-guideline/candidiasis/","Infectious Diseases Society of America","guideline","2016-02-15",{"sourceId":178,"title":179,"canonicalId":180,"canonicalUrl":181,"publisher":182,"sourceType":183,"publicationDate":184,"lastChecked":21},"lacour-intestinal-candida-systematic-review-2002","The pathogenetic significance of intestinal Candida colonization: a systematic review from an interdisciplinary and environmental medical point of view","PMID:12068745; DOI:10.1078/1438-4639-00159","https://pubmed.ncbi.nlm.nih.gov/12068745/","International Journal of Hygiene and Environmental Health","systematic-review","2002-05-01",{"sourceId":186,"title":187,"canonicalId":188,"canonicalUrl":189,"publisher":190,"sourceType":191,"publicationDate":192,"lastChecked":21},"dismukes-nystatin-candidiasis-hypersensitivity-1990","A randomized, double-blind trial of nystatin therapy for the candidiasis hypersensitivity syndrome","PMID:2247104; DOI:10.1056/NEJM199012203232501","https://pubmed.ncbi.nlm.nih.gov/2247104/","New England Journal of Medicine","randomized-trial","1990-12-20",{"sourceId":194,"title":195,"canonicalId":196,"canonicalUrl":197,"publisher":198,"sourceType":199,"publicationDate":200,"lastChecked":21},"jacobs-small-intestinal-overgrowth-2013","Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth","PMID:23574267; DOI:10.1111/apt.12304","https://pubmed.ncbi.nlm.nih.gov/23574267/","Alimentary Pharmacology & Therapeutics","observational-study","2013-06-01",{"sourceId":202,"title":203,"canonicalId":204,"canonicalUrl":205,"publisher":206,"sourceType":207,"publicationDate":208,"lastChecked":21},"erdogan-sifo-review-2015","Small intestinal fungal overgrowth","PMID:25786900; DOI:10.1007/s11894-015-0436-2","https://pubmed.ncbi.nlm.nih.gov/25786900/","Current Gastroenterology Reports","other","2015-04-01",{"sourceId":210,"title":211,"canonicalId":212,"canonicalUrl":213,"publisher":214,"sourceType":163,"publicationDate":215,"lastChecked":21},"fda-dietary-supplements-2022","FDA 101: Dietary Supplements","FDA consumer update: FDA 101 Dietary Supplements","https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements","U.S. Food and Drug Administration","2022-06-02",{"sourceId":217,"title":218,"canonicalId":219,"canonicalUrl":220,"publisher":214,"sourceType":163,"publicationDate":215,"lastChecked":21},"fda-mixing-supplements-medications-2022","Mixing Medications and Dietary Supplements Can Endanger Your Health","FDA consumer update: mixing medications and dietary supplements","https://www.fda.gov/consumers/consumer-updates/mixing-medications-and-dietary-supplements-can-endanger-your-health",[222,240,253,264,274,286],{"claimId":55,"exactClaim":223,"outcome":224,"population":225,"verdict":226,"evidenceLevel":227,"rationale":228,"safetyStatus":229,"evidenceAsOf":21,"lastUpdated":21,"status":230,"changeHistory":231,"sources":232},"A broad cluster of nonspecific symptoms such as fatigue, bloating, altered bowel habits, concentration difficulty, mood symptoms, cravings, or skin complaints establishes intestinal Candida overgrowth as their shared cause.","valid causal attribution of a nonspecific multisystem symptom cluster to intestinal Candida overgrowth","immunocompetent adolescents and adults with chronic gastrointestinal and/or extraintestinal symptoms but without established site-specific or invasive candidiasis","not-supported","moderate","A systematic review of 96 eligible citations found intestinal Candida colonization common in healthy immunocompetent adults and found neither epidemiologic nor therapeutic evidence for a Candida or Candida-hypersensitivity syndrome. Current CDC and IDSA disease definitions do not recognize a symptom-list diagnosis of systemic or intestinal candidiasis. The controlled nystatin trial in women meeting proposed candidiasis-hypersensitivity criteria found no meaningful advantage over placebo for systemic or psychological symptoms. Early SIFO studies concern a narrower, selected gastrointestinal population assessed by small-bowel aspirate and cannot validate a broad multisystem syndrome. Plausible alternatives depend on the symptom pattern and include functional gastrointestinal disorders, medication effects, dietary intolerance, endocrine or hematologic disease, dermatologic conditions, sleep or mood disorders, and other infections; the attribution should stop and pivot to evaluation of the actual symptoms when a recognized Candida condition has not been established.","usual-cautions","active",[],[233,234,235,236,237,238,239],{"title":179,"canonicalId":180,"canonicalUrl":181,"publisher":182,"sourceType":183,"publicationDate":184,"lastChecked":21},{"title":159,"canonicalId":160,"canonicalUrl":161,"publisher":162,"sourceType":163,"publicationDate":164,"lastChecked":21},{"title":167,"canonicalId":160,"canonicalUrl":168,"publisher":162,"sourceType":163,"publicationDate":164,"lastChecked":21},{"title":171,"canonicalId":172,"canonicalUrl":173,"publisher":174,"sourceType":175,"publicationDate":176,"lastChecked":21},{"title":187,"canonicalId":188,"canonicalUrl":189,"publisher":190,"sourceType":191,"publicationDate":192,"lastChecked":21},{"title":195,"canonicalId":196,"canonicalUrl":197,"publisher":198,"sourceType":199,"publicationDate":200,"lastChecked":21},{"title":203,"canonicalId":204,"canonicalUrl":205,"publisher":206,"sourceType":207,"publicationDate":208,"lastChecked":21},{"claimId":241,"exactClaim":242,"outcome":243,"population":244,"verdict":245,"evidenceLevel":246,"rationale":247,"safetyStatus":229,"evidenceAsOf":21,"lastUpdated":21,"status":230,"changeHistory":248,"sources":249},"candidiasis-is-site-specific-disease-not-candida-presence","Candidiasis names disease caused by Candida at a defined body site; the presence of Candida on skin or in the mouth, gastrointestinal tract, or vagina without compatible disease does not itself establish candidiasis.","correct distinction between recognized site-specific candidiasis and asymptomatic Candida carriage or colonization","adolescents and adults encountering Candida terminology or a Candida finding from a nonsterile body site","supported","strong","CDC describes Candida as normally present at several body sites and candidiasis as infection when it causes site-dependent disease. CDC and IDSA separately describe gastrointestinal, skin, and respiratory colonization and do not equate a nonsterile-site finding with invasive or mucosal disease.",[],[250,251,252],{"title":159,"canonicalId":160,"canonicalUrl":161,"publisher":162,"sourceType":163,"publicationDate":164,"lastChecked":21},{"title":167,"canonicalId":160,"canonicalUrl":168,"publisher":162,"sourceType":163,"publicationDate":164,"lastChecked":21},{"title":171,"canonicalId":172,"canonicalUrl":173,"publisher":174,"sourceType":175,"publicationDate":176,"lastChecked":21},{"claimId":254,"exactClaim":255,"outcome":256,"population":257,"verdict":245,"evidenceLevel":246,"rationale":258,"safetyStatus":229,"evidenceAsOf":21,"lastUpdated":21,"status":230,"changeHistory":259,"sources":260},"invasive-candidiasis-is-not-vernacular-systemic-candida","Recognized invasive candidiasis is infection of the bloodstream or normally sterile internal sites in high-risk clinical populations; it is not a synonym for a self-attributed chronic multisystem symptom pattern called 'systemic Candida' or 'whole-body Candida overgrowth.'","accurate separation of invasive candidiasis from vernacular broad-overgrowth labels","adolescents and adults using broad Candida terminology for chronic gastrointestinal, fatigue, cognitive, mood, skin, or other nonspecific symptoms","CDC and IDSA define invasive candidiasis by invasive disease entities, risk context, cultures, and affected sterile sites. Their definitions do not map nonspecific chronic symptom lists in otherwise stable community populations to invasive candidiasis. This terminology boundary does not rule out a person's symptoms; it stops the invasive-disease label from being inferred from them.",[],[261,262,263],{"title":159,"canonicalId":160,"canonicalUrl":161,"publisher":162,"sourceType":163,"publicationDate":164,"lastChecked":21},{"title":167,"canonicalId":160,"canonicalUrl":168,"publisher":162,"sourceType":163,"publicationDate":164,"lastChecked":21},{"title":171,"canonicalId":172,"canonicalUrl":173,"publisher":174,"sourceType":175,"publicationDate":176,"lastChecked":21},{"claimId":265,"exactClaim":266,"outcome":267,"population":268,"verdict":226,"evidenceLevel":269,"rationale":270,"safetyStatus":229,"evidenceAsOf":21,"lastUpdated":21,"status":230,"changeHistory":271,"sources":272},"nystatin-broad-candida-systemic-symptoms","Oral nystatin improves systemic or psychological symptoms more than placebo in women meeting proposed criteria for candidiasis hypersensitivity syndrome.","change in systemic symptom scores and standardized psychological symptom or distress measures","adult women with recurrent or persistent vaginal Candida history and systemic symptoms who met the trial's proposed candidiasis-hypersensitivity criteria, excluding invasive disease and major immunocompromising conditions","unclear","In the randomized double-blind crossover trial, systemic symptoms improved similarly with active nystatin and placebo (25% versus 23%; between-group difference 2%, 95% CI -3% to 7%), and psychological outcomes did not differ. The result directly addresses this drug and trial-defined population, not every proposed Candida intervention or every cause of the participants' symptoms.",[],[273],{"title":187,"canonicalId":188,"canonicalUrl":189,"publisher":190,"sourceType":191,"publicationDate":192,"lastChecked":21},{"claimId":275,"exactClaim":276,"outcome":277,"population":278,"verdict":245,"evidenceLevel":279,"rationale":280,"safetyStatus":229,"evidenceAsOf":21,"lastUpdated":21,"status":230,"changeHistory":281,"sources":282},"sifo-is-narrow-clinical-research-entity","Small intestinal fungal overgrowth (SIFO) is a narrow clinical-research label for excessive fungal growth detected in small-intestinal aspirate in a person with gastrointestinal symptoms; it is not interchangeable with normal gut Candida carriage, invasive candidiasis, or a broad multisystem 'Candida overgrowth' syndrome.","correct identification of the population, sampling site, and disease boundaries represented by the term SIFO","adults with persistent otherwise-unexplained gastrointestinal symptoms considered for specialist small-intestinal evaluation","early","The 2013 single-center study and 2015 clinical review consistently use SIFO for fungal growth from duodenal or small-intestinal aspirate in selected symptomatic patients. The literature is small, largely from one investigator group, and lacks a standardized diagnostic protocol, so this supports a terminology boundary rather than a mature broadly applicable diagnosis.",[],[283,284,285],{"title":195,"canonicalId":196,"canonicalUrl":197,"publisher":198,"sourceType":199,"publicationDate":200,"lastChecked":21},{"title":203,"canonicalId":204,"canonicalUrl":205,"publisher":206,"sourceType":207,"publicationDate":208,"lastChecked":21},{"title":167,"canonicalId":160,"canonicalUrl":168,"publisher":162,"sourceType":163,"publicationDate":164,"lastChecked":21},{"claimId":287,"exactClaim":288,"outcome":289,"population":290,"verdict":245,"evidenceLevel":246,"rationale":291,"safetyStatus":229,"evidenceAsOf":21,"lastUpdated":21,"status":230,"changeHistory":292,"sources":293},"candida-detection-alone-does-not-establish-vvc","Detecting Candida in a vaginal sample without compatible symptoms and signs does not by itself establish symptomatic vulvovaginal candidiasis because asymptomatic colonization occurs.","distinction between asymptomatic Candida colonization and symptomatic vulvovaginal candidiasis","adolescents and adults with Candida detected in a vaginal sample, including those with minimal, nonspecific, or absent symptoms","CDC diagnostic guidance and the ISSVD guideline explicitly distinguish Candida detection or positive culture from symptomatic infection and do not treat asymptomatic detection as proof of disease.",[],[294,299,302],{"title":295,"canonicalId":296,"canonicalUrl":297,"publisher":162,"sourceType":175,"publicationDate":298,"lastChecked":21},"Sexually Transmitted Infections Treatment Guidelines, 2021: Vulvovaginal Candidiasis","doi:10.15585/mmwr.rr7004a1","https://www.cdc.gov/std/treatment-guidelines/candidiasis.htm","2021-07-23",{"title":300,"canonicalId":160,"canonicalUrl":301,"publisher":162,"sourceType":163,"publicationDate":164,"lastChecked":21},"Testing and Diagnosis for Candidiasis","https://www.cdc.gov/candidiasis/testing/index.html",{"title":303,"canonicalId":304,"canonicalUrl":305,"publisher":306,"sourceType":175,"publicationDate":307,"lastChecked":21},"International Society for the Study of Vulvovaginal Disease Recommendations for the Diagnosis and Treatment of Vaginitis","doi:10.59153/adm.rdtv.001","https://www.issvd.org/resources/recommendations-for-the-diagnosis-and-treatment-of-vaginitis","International Society for the Study of Vulvovaginal Disease","2023-03-01",[309],{"safetyId":310,"observableTrigger":311,"careTier":312,"action":313,"applicablePopulations":314,"excludedPopulations":316,"locale":6,"checkedAt":21,"expiresAt":319,"sources":320},"us-candida-supplement-review-routine","Before starting a dietary supplement marketed for Candida, biofilms, die-off, gut health, or probiotic effects, the person takes a prescription or over-the-counter medicine, uses another supplement, is pregnant or breastfeeding, is a child, or has planned surgery or a recent change in health.","routine","Ask a physician, pharmacist, registered dietitian, or other qualified health professional to review the exact product label, full medicine and supplement list, health conditions, and planned surgery before use.",[315],"people in the United States considering an ingestible dietary supplement marketed for a Candida-related purpose who meet at least one listed trigger",[317,318],"people considering a conventional food rather than a dietary supplement","users with a serious reaction or acute crisis, who need the applicable faster route","2027-01-15",[321,322],{"title":211,"canonicalId":212,"canonicalUrl":213,"publisher":214,"sourceType":163,"publicationDate":215,"lastChecked":21},{"title":218,"canonicalId":219,"canonicalUrl":220,"publisher":214,"sourceType":163,"publicationDate":215,"lastChecked":21},[324,327,330],{"rel":325,"hreflang":6,"href":326},"alternate","https://candipedia.org/en/treatments-evidence/candida-overgrowth-claim/",{"rel":325,"hreflang":328,"href":329},"pl-PL","https://candipedia.org/pl/metody-i-dowody/twierdzenie-o-przeroscie-candidy/",{"rel":325,"hreflang":331,"href":326},"x-default",1784685064880]